コンパニオン診断薬市場：技術、適応症、エンドユーザー別-2025-2030年の世界予測

コンパニオン診断薬市場は、2023年に66億4,000万米ドルと評価され、2024年には73億米ドルに達すると予測され、CAGR 10.65％で成長し、2030年には134億9,000万米ドルに達すると予測されています。

精密医療の重要な側面であるコンパニオン診断薬は、治療に対する反応を示すバイオマーカーを特定することで、患者に対する特定の治療の適合性と有効性を判断するように設計された臨床検査またはアッセイを指します。コンパニオン診断薬のニーズは、個別化医療がますます重視されるようになり、副作用を減らしつつ、効率的な患者の転帰のために的を絞った治療法を確保するために高まっています。その用途は広範で、腫瘍学、免疫学、感染症に顕著に見られ、オーダーメイド治療が患者の予後を大幅に改善します。エンドユーザーには主に病院、診断研究所、製薬会社などが含まれ、これらの企業は治療プロトコルの強化や研究能力の向上にこれらのツールを活用しています。市場開拓の原動力となるのは、技術革新、がん罹患率の上昇、精密医療を推進する政府のイニシアティブ、薬剤-診断共同開発への製薬企業の投資拡大などです。潜在的なビジネスチャンスとしては、これらの診断薬で発見可能な適応症の拡大、診断薬企業と医薬品メーカーとの提携、ヘルスケアインフラが整備された新興市場における需要の増加などが挙げられます。しかしながら、開発コストの高さ、規制の複雑さ、償還制度の制限といった課題もあり、これらは市場の拡大やアクセシビリティの妨げとなる可能性があります。技術革新の重要な分野は、非侵襲的リキッドバイオプシー検査の開発と、予測診断のための複雑なデータを分析するAIと機械学習の統合にあります。企業は、既存の限界に対処しつつ新たな機会を活用するため、戦略的提携と規制経路のナビゲーションに注力すべきです。市場の特性を理解することは極めて重要です。市場の競争は激しく、ダイナミックであり、急速な技術進歩や製薬・診断部門間の継続的な共同開発の必要性に後押しされています。このような技術革新と課題に戦略を合わせることで、企業は進化するプレシジョン・ヘルスケアの展望の中で、コンパニオン診断薬の成長ポテンシャルを効果的に活用することができます。

市場力学：急速に進化するコンパニオン診断薬市場の主要市場インサイトを公開

コンパニオン診断薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 医薬品開発におけるコンパニオン診断薬の重要性の高まり
  • 個別化医薬品と標的治療に対する需要の高まり
  • 次世代シーケンサーの革新に向けた研究開発の活発化
• 市場抑制要因
  • コンパニオン診断薬の開発および実装に伴う高コスト
• 市場機会
  • 診断技術における継続的な技術進歩
  • コンパニオン診断薬の開発と認可を奨励する有利な規制政策
• 市場の課題
  • コンパニオン診断検査に関連する償還の問題

ポーターのファイブフォース：コンパニオン診断薬市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：コンパニオン診断薬市場における外部からの影響の把握

外部マクロ環境要因は、コンパニオン診断薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析コンパニオン診断薬市場における競合情勢の把握

コンパニオン診断薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスコンパニオン診断薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、コンパニオン診断薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨コンパニオン診断薬市場における成功への道筋を描く

コンパニオン診断薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 医薬品開発におけるコンパニオン診断薬の重要性の高まり
    • 個別化医薬品と標的療法の需要増加
    • 次世代シーケンシングの革新に向けた研究開発の高まり
  • 抑制要因
    • コンパニオン診断薬の開発と実装に関連する高コスト
  • 機会
    • 診断技術における継続的な技術的進歩
    • コンパニオン診断薬の開発と承認を促進する有利な規制政策
  • 課題
    • コンパニオン診断検査に関連する償還問題
• 市場セグメンテーション分析
  • テクノロジー：精密医療における次世代シーケンシングの好感度が増加
  • エンドユーザー：製薬およびバイオ医薬品セクターの拡大がコンパニオン診断薬の重要性を推進
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 コンパニオン診断薬市場：技術別

• 免疫組織化学
• インサイチューハイブリダイゼーション
• 次世代シーケンシング
• ポリメラーゼ連鎖反応

第7章 コンパニオン診断薬市場適応症別

• がん
  • 血液がん
  • 乳がん
  • 大腸がん
  • 肺がん
• 心血管疾患
• 感染症
• 神経疾患

第8章 コンパニオン診断薬市場：エンドユーザー別

• 製薬・バイオ医薬品企業
• リファレンスラボ

第9章 南北アメリカのコンパニオン診断薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域のコンパニオン診断薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカのコンパニオン診断薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • サーモフィッシャーサイエンティフィックとバイエルの革新的な提携により、精密がん治療の新たな基準が確立
  • アジレントと洞察の戦略的提携によりコンパニオン診断の開発が促進される
  • 新たな治療の展望を開く：FDAが進行性乳がんに対するCapivasertibとフルベストラントの併用を承認、FoundationOne（R）CDx診断の進歩が支援
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• Abnova Corporation
• Agendia, Inc.
• Agilent Technologies, Inc.
• Almac Group
• Amoy Diagnostics Co., Ltd.
• ARUP Laboratories
• Bio-Techne Corporation
• Biogenex Laboratories, Inc
• bioMerieux SA
• Danaher Corporation
• Eli Lilly and Company
• F. Hoffmann-La Roche AG
• Guardant Health, Inc
• ICON PLC
• Illumina, Inc.
• Invivoscribe Technologies, Inc.
• Myriad Genetics, Inc.
• NG biotech
• QIAGEN N.V.
• R-Biopharm AG
• Siemens AG
• Sysmex Corporation
• Thermo Fisher Scientific Inc.

LIST OF FIGURES

• FIGURE 1. COMPANION DIAGNOSTICS MARKET RESEARCH PROCESS
• FIGURE 2. COMPANION DIAGNOSTICS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. COMPANION DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. COMPANION DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. COMPANION DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. COMPANION DIAGNOSTICS MARKET DYNAMICS
• TABLE 7. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY IN SITU HYBRIDIZATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY BLOOD CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 30. ARGENTINA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 31. ARGENTINA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 32. ARGENTINA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 33. ARGENTINA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 34. BRAZIL COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 35. BRAZIL COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 36. BRAZIL COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 37. BRAZIL COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 38. CANADA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 39. CANADA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 40. CANADA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 41. CANADA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 42. MEXICO COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 43. MEXICO COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 44. MEXICO COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 45. MEXICO COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 46. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 47. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 48. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 49. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 50. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 51. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 52. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 53. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 54. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 55. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 56. AUSTRALIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 57. AUSTRALIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 58. AUSTRALIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 59. AUSTRALIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 60. CHINA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 61. CHINA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 62. CHINA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 63. CHINA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 64. INDIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 65. INDIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 66. INDIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 67. INDIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 68. INDONESIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 69. INDONESIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 70. INDONESIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 71. INDONESIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 72. JAPAN COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 73. JAPAN COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 74. JAPAN COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 75. JAPAN COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 76. MALAYSIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 77. MALAYSIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 78. MALAYSIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 79. MALAYSIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 80. PHILIPPINES COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 81. PHILIPPINES COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 82. PHILIPPINES COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 83. PHILIPPINES COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 84. SINGAPORE COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 85. SINGAPORE COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 86. SINGAPORE COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 87. SINGAPORE COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 88. SOUTH KOREA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 89. SOUTH KOREA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 90. SOUTH KOREA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 91. SOUTH KOREA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 92. TAIWAN COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 93. TAIWAN COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 94. TAIWAN COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 95. TAIWAN COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 96. THAILAND COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 97. THAILAND COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 98. THAILAND COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 99. THAILAND COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 100. VIETNAM COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 101. VIETNAM COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 102. VIETNAM COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 103. VIETNAM COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 104. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 105. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 106. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 107. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 108. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 109. DENMARK COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 110. DENMARK COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 111. DENMARK COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 112. DENMARK COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 113. EGYPT COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 114. EGYPT COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 115. EGYPT COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 116. EGYPT COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 117. FINLAND COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 118. FINLAND COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 119. FINLAND COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 120. FINLAND COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 121. FRANCE COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 122. FRANCE COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 123. FRANCE COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 124. FRANCE COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 125. GERMANY COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 126. GERMANY COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 127. GERMANY COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 128. GERMANY COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 129. ISRAEL COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 130. ISRAEL COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 131. ISRAEL COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 132. ISRAEL COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 133. ITALY COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 134. ITALY COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 135. ITALY COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 136. ITALY COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 137. NETHERLANDS COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 138. NETHERLANDS COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 139. NETHERLANDS COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 140. NETHERLANDS COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 141. NIGERIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 142. NIGERIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 143. NIGERIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 144. NIGERIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 145. NORWAY COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 146. NORWAY COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 147. NORWAY COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 148. NORWAY COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 149. POLAND COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 150. POLAND COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 151. POLAND COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 152. POLAND COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 153. QATAR COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 154. QATAR COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 155. QATAR COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 156. QATAR COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 157. RUSSIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 158. RUSSIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 159. RUSSIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 160. RUSSIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 161. SAUDI ARABIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 162. SAUDI ARABIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 163. SAUDI ARABIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 164. SAUDI ARABIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 165. SOUTH AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 166. SOUTH AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 167. SOUTH AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 168. SOUTH AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 169. SPAIN COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 170. SPAIN COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 171. SPAIN COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 172. SPAIN COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 173. SWEDEN COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 174. SWEDEN COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 175. SWEDEN COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 176. SWEDEN COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 177. SWITZERLAND COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 178. SWITZERLAND COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 179. SWITZERLAND COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 180. SWITZERLAND COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 181. TURKEY COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 182. TURKEY COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 183. TURKEY COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 184. TURKEY COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 185. UNITED ARAB EMIRATES COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 186. UNITED ARAB EMIRATES COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 187. UNITED ARAB EMIRATES COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 188. UNITED ARAB EMIRATES COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 189. UNITED KINGDOM COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 190. UNITED KINGDOM COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 191. UNITED KINGDOM COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 192. UNITED KINGDOM COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 193. COMPANION DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 194. COMPANION DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

The Companion Diagnostics Market was valued at USD 6.64 billion in 2023, expected to reach USD 7.30 billion in 2024, and is projected to grow at a CAGR of 10.65%, to USD 13.49 billion by 2030.

Companion diagnostics, a vital aspect of precision medicine, refer to laboratory tests or assays designed to determine the suitability and effectiveness of a specific treatment for a patient by identifying biomarkers that indicate response to therapy. The need for companion diagnostics is growing owing to the increasing emphasis on personalized medicine, ensuring targeted therapeutics for efficient patient outcomes while reducing adverse effects. Their applications are expansive, prominently seen in oncology, immunology, and infectious diseases, where tailored treatments can significantly improve patient prognoses. End-user segments primarily include hospitals, diagnostic laboratories, and pharmaceutical companies, which utilize these tools for enhancing treatment protocols and research capabilities. Market growth is fueled by technological innovations, rising cancer prevalence, governmental initiatives promoting precision medicine, and expanding pharmaceutical investments in drug-diagnostic co-development. Potential opportunities include expanding indications discoverable by these diagnostics, partnerships between diagnostic firms and drug manufacturers, and increased demand in emerging markets with improving healthcare infrastructures. Nonetheless, challenges include high development costs, regulatory complexities, and limited reimbursement frameworks, which can hinder market expansion and accessibility. A critical area of innovation lies in the development of non-invasive liquid biopsy tests and integration of AI and machine learning to analyze complex data for predictive diagnostics. Companies should focus on strategic collaborations and regulatory pathway navigation to capitalize on emerging opportunities while addressing existing limitations. Understanding the nature of the market is crucial-it is highly competitive and dynamic, driven by rapid technological advancements and the continuous need for collaborative development between the pharmaceutical and diagnostic sectors. By aligning strategies with these innovations and challenges, businesses can effectively harness the growth potential of companion diagnostics in the evolving landscape of precision healthcare.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Companion Diagnostics Market

The Companion Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing significance of companion diagnostics in drug development
  • Increasing demand for personalized medicines and targeted therapy
  • Rise in research and development for innovation in next generation sequencing
• Market Restraints
  • High costs associated with development and implementation of companion diagnostics
• Market Opportunities
  • Ongoing technological advancements in diagnostic techniques
  • Favorable regulatory policies encouraging the development and approval of companion diagnostics
• Market Challenges
  • Reimbursement issues associated with companion diagnostic tests

Porter's Five Forces: A Strategic Tool for Navigating the Companion Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Companion Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Companion Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Companion Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Companion Diagnostics Market

A detailed market share analysis in the Companion Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Companion Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Companion Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Companion Diagnostics Market

A strategic analysis of the Companion Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Companion Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Abnova Corporation, Agendia, Inc., Agilent Technologies, Inc., Almac Group, Amoy Diagnostics Co., Ltd., ARUP Laboratories, Bio-Techne Corporation, Biogenex Laboratories, Inc, bioMerieux SA, Danaher Corporation, Eli Lilly and Company, F. Hoffmann-La Roche AG, Guardant Health, Inc, ICON PLC, Illumina, Inc., Invivoscribe Technologies, Inc., Myriad Genetics, Inc., NG biotech, QIAGEN N.V., R-Biopharm AG, Siemens AG, Sysmex Corporation, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Companion Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Technology, market is studied across Immunohistochemistry, In Situ Hybridization, Next-Generation Sequencing, and Polymerase Chain Reaction.
• Based on Indication, market is studied across Cancer, Cardiovascular Diseases, Infectious Diseases, and Neurological Disorders. The Cancer is further studied across Blood Cancer, Breast Cancer, Colorectal Cancer, and Lung Cancer.
• Based on End-user, market is studied across Pharmaceutical & Biopharmaceutical Companies and Reference Laboratories.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing significance of companion diagnostics in drug development
    • 5.1.1.2. Increasing demand for personalized medicines and targeted therapy
    • 5.1.1.3. Rise in research and development for innovation in next generation sequencing
  • 5.1.2. Restraints
    • 5.1.2.1. High costs associated with development and implementation of companion diagnostics
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing technological advancements in diagnostic techniques
    • 5.1.3.2. Favorable regulatory policies encouraging the development and approval of companion diagnostics
  • 5.1.4. Challenges
    • 5.1.4.1. Reimbursement issues associated with companion diagnostic tests
• 5.2. Market Segmentation Analysis
  • 5.2.1. Technology: Increasing preference of next-generation sequencing in precision medicine
  • 5.2.2. End-user: Expansion of pharmaceutical and biopharmaceutical sector driving the significance of companion diagnostics
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Companion Diagnostics Market, by Technology

• 6.1. Introduction
• 6.2. Immunohistochemistry
• 6.3. In Situ Hybridization
• 6.4. Next-Generation Sequencing
• 6.5. Polymerase Chain Reaction

7. Companion Diagnostics Market, by Indication

• 7.1. Introduction
• 7.2. Cancer
  • 7.2.1. Blood Cancer
  • 7.2.2. Breast Cancer
  • 7.2.3. Colorectal Cancer
  • 7.2.4. Lung Cancer
• 7.3. Cardiovascular Diseases
• 7.4. Infectious Diseases
• 7.5. Neurological Disorders

8. Companion Diagnostics Market, by End-user

• 8.1. Introduction
• 8.2. Pharmaceutical & Biopharmaceutical Companies
• 8.3. Reference Laboratories

9. Americas Companion Diagnostics Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Companion Diagnostics Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Companion Diagnostics Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. Innovative Partnership Between Thermo Fisher Scientific and Bayer Sets New Standard in Precision Cancer Care
  • 12.3.2. Strategic Partnership between Agilent and Incyte Elevates Companion Diagnostic Development
  • 12.3.3. Unlocking New Treatment Horizons: FDA Approves Capivasertib & Fulvestrant Combo for Advanced Breast Cancer, Backed by FoundationOne(R) CDx Diagnostic Advances
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Abnova Corporation
• 3. Agendia, Inc.
• 4. Agilent Technologies, Inc.
• 5. Almac Group
• 6. Amoy Diagnostics Co., Ltd.
• 7. ARUP Laboratories
• 8. Bio-Techne Corporation
• 9. Biogenex Laboratories, Inc
• 10. bioMerieux SA
• 11. Danaher Corporation
• 12. Eli Lilly and Company
• 13. F. Hoffmann-La Roche AG
• 14. Guardant Health, Inc
• 15. ICON PLC
• 16. Illumina, Inc.
• 17. Invivoscribe Technologies, Inc.
• 18. Myriad Genetics, Inc.
• 19. NG biotech
• 20. QIAGEN N.V.
• 21. R-Biopharm AG
• 22. Siemens AG
• 23. Sysmex Corporation
• 24. Thermo Fisher Scientific Inc.